血清癌胚抗原水平可预测表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）对携带EGFR突变的非小细胞肺癌的疗效。
Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations.
作者信息
Yanwei Zhang, Bo Jin, Yuqing Lou, Rong Li, Xueyan Zhang, Song Hu, Baohui Han
机构信息
Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic China.
出版信息
J Cancer Res Ther. 2016 Jan-Mar;12(1):254-8. doi: 10.4103/0973-1482.153666.
OBJECTIVES
Not all the patients harboring epidermal growth factor receptor (EGFR) mutations have a clinical response after the treatment of EGFR-tyrosine kinase inhibitor (TKI). The purpose of the present study was to find whether the baseline carcinoembryonic antigen (CEA) levels were associated with the efficacy of EGFR-TKI in patients harboring EGFR mutations.
MATERIALS AND METHODS
Clinical features, serum tumor marker levels, and survival time were analyzed, retrospectively, in 200 non-small cell lung cancer (NSCLC) patients harboring EGFR mutations treated with EGFR-TKI.
RESULTS
The total objective response rate (ORR) is 44.0% and disease control rate is 84.5%. The disease control rate in the patients with high CEA levels was significantly higher than that with low CEA levels (88.3 vs 74.5%, P = 0.029). There was no significant difference in progression-free survival (PFS) between high (≥5 ng/ml) and normal CEA groups (< ng/ml; 12.0 vs 8.3m, and P = 0.055). The PFS in patients with higher CEA levels (≥ 20 ng/ml) was longer than in patients with lower CEA levels (< ng/ml; 12.8 vs 8.7m, P = 0.016). Multivariate analysis shows that high CEA level (> ng/ml) were independent predictive factors for PFS (HR = 1.412, 93% CI: 1.042-1.913, P = 0.026).
CONCLUSIONS
Baseline serum CEA levels can serve as predictive factors for the treatment of EGFR-TKI in NSCLC patients harboring EGFR mutations.
目的
并非所有携带表皮生长因子受体（EGFR）突变的患者在接受EGFR酪氨酸激酶抑制剂（TKI）治疗后都有临床反应。本研究的目的是探讨基线癌胚抗原（CEA）水平是否与携带EGFR突变患者的EGFR-TKI疗效相关。
材料与方法
回顾性分析200例接受EGFR-TKI治疗的携带EGFR突变的非小细胞肺癌（NSCLC）患者的临床特征、血清肿瘤标志物水平和生存时间。
结果
总客观缓解率（ORR）为44.0%，疾病控制率为84.5%。CEA水平高的患者疾病控制率显著高于CEA水平低的患者（88.3%对74.5%，P = 0.029）。高CEA水平（≥5 ng/ml）组与正常CEA水平组（< ng/ml）的无进展生存期（PFS）无显著差异（12.0对8.3个月，P = 0.055）。CEA水平较高（≥20 ng/ml）的患者的PFS长于CEA水平较低（< ng/ml）的患者（12.8对8.7个月，P = 0.016）。多因素分析显示，高CEA水平（> ng/ml）是PFS的独立预测因素（HR = 1.412，93%CI：1.042 - 1.913，P = 0.026）。
结论
基线血清CEA水平可作为携带EGFR突变的NSCLC患者EGFR-TKI治疗的预测因素。
Zotero 插件